ClinicalTrials.gg

Tuberculosis, Multidrug-Resistant clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 132 studies for Tuberculosis, Multidrug-Resistant across more than 10 countries. 25 are recruiting or about to start. 88 of them are mainly about Tuberculosis, Multidrug-Resistant (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10. Counting its narrower condition Extensively Drug-Resistant Tuberculosis too: 133 studies, 25 open.

Status

Completed
78
Recruiting
20
Status unknown
15
Terminated
7
Not yet recruiting
5
Active, not recruiting
4

Phase

Phase 2
33
Phase 3
32
Phase 4
9
Phase 1
8

Where

South Africa
46
China
26
Peru
19
Philippines
16
Georgia
13
India
11

Who develops what

Add Tuberculosis, Multidrug-Resistant to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 1 program from 1 company, 1 with this as their studies’ main aim; 1 with a live phase 3 study; 0 primary completions in the next 12 months.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
bedaquilineRecent, repeated
Evidence
  • NCT07209761 · Otsuka Holdings Co., Ltd. · Phase 3 · live · background · “Bedaquiline” · registered Aug 2025
  • NCT05824871 · Shanghai Jiatan Pharmatech Co., Ltd · Phase 3 · live · comparator · “Bedaquiline” · registered Apr 2023
  • NCT01600963 · Janssen Infectious Diseases BVBA · Phase 3 · background · “Treatment Failure During Follow-up Phase: TMC207” · registered Apr 2012
Johnson & Johnson69% of its industry studiesUS: JANSSEN THERAP (FDA 2012)22 studies

2 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 1 program — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (0)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

None in the next 12 months.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Tuberculosis, Multidrug-Resistant studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Coming up

10studies finish main data collection within a year3 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 10, phase 3 first

Who these studies take

Of the 20 Tuberculosis, Multidrug-Resistant studies recruiting now, 12 (60%) set no upper age limit and 7 (35%) stop at 75 or younger. 9 (45%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 2 (10%) take healthy volunteers.

Recruiting studies that take each age, of 20
AgeWomenMen
105 (25%)5 (25%)
1819 (95%)19 (95%)
3020 (100%)20 (100%)
4020 (100%)20 (100%)
5020 (100%)20 (100%)
6519 (95%)19 (95%)
7515 (75%)15 (75%)
8513 (65%)13 (65%)

Across all 132 studies, recruiting or not: 31% stop at 75 or younger and 20% at 65; 34% take children; 0% are for women only and 1% for men only; 11% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Tuberculosis, Multidrug-Resistant studies take

Of 19 observational studies under Tuberculosis, Multidrug-Resistant, half reached primary completion within 53 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Observational53 mo32–90 · 19 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 132. Browse all 132 → or search them.